AGP Executive Report
Last update: 9 hours agoEU Health Policy Watch: The European Evangelical Alliance is raising alarms about moves to liberalize abortion access in Andorra and Liechtenstein, including Andorra’s plan to decriminalize abortions obtained abroad and Liechtenstein’s narrowly backed proposal for abortion in the first 12 weeks. Rare Disease Treatment: The EU has granted marketing authorisation for Nezglyal for childhood cerebral adrenoleukodystrophy (male, ages 2–12) with Gd-negative brain lesions—described as the first pharmacological option for early intervention in this aggressive neurodegenerative disease. Drug Pricing & Trade: The US has exempted certain specialty medicines and key ingredients from a planned 100% tariff under Section 232, with qualifying categories including orphan drugs, nuclear medicines, cell and gene therapies, and antibody-drug conjugates—covering origins such as Switzerland and Liechtenstein. Mobility & Health Workforce Links: India and Switzerland signed a migration and mobility partnership plus young professionals exchanges, with multiple-entry visas up to five years—potentially easing cross-border movement of students and skilled workers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
